Comparing RPH-030 to Vectibix for metastatic colorectal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests whether a new drug called RPH-030 works similarly to an existing drug called Vectibix in treating advanced colorectal cancer that has spread. Both drugs will be given alongside chemotherapy (FOLFIRI) as a first-line treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have metastatic colorectal cancer (cancer that has spread) confirmed by biopsy, and it is your first time receiving systemic cancer treatment
- Your cancer has wild-type RAS (a genetic marker that makes you eligible for this type of treatment)
- You have good overall health (ECOG performance status 0–1, meaning you can do most daily activities)
- You have at least one measurable tumor on scans (not just bone lesions)
- Your blood counts, kidney function, and liver function are adequate for chemotherapy
- You are willing to use effective birth control for at least 2–6 months after treatment ends if you can become pregnant
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests new treatment combinations for colorectal cancer that has spread (metastatic). It is for people whose cancer is mismatch repair proficient (pMMR) or microsatellite stable (MSS) and who have not had previous treatment for metastatic disease.
This trial tests a new drug called RBS2418 for people with advanced colorectal cancer that has spread and is getting worse, even after other treatments have stopped working. The goal is to see if RBS2418 can help control the cancer.
This study tests a new combination of short-course radiation followed by two targeted drugs (fruquintinib and sintilimab) compared to standard therapy (bevacizumab and capecitabine) for people with advanced colorectal cancer who cannot tolerate strong chemotherapy. It aims to see if this gentler approach works as well or better.
This trial tests adding a new immunotherapy drug (QL1706) to standard chemotherapy plus bevacizumab for people with colorectal cancer that has spread and hasn't been treated yet. It aims to see if the combination works better than standard treatment alone.
This trial tests a new drug, ivonescimab, combined with chemotherapy for people whose colorectal cancer has spread to other parts of the body but not to the liver. The goal is to see if this combination works better than current treatments for this specific type of cancer.
This trial tests a combination of three drugs (irinotecan liposomes, cetuximab, and vemurafenib) for people with advanced colorectal cancer that has a specific genetic change (BRAF V600E mutation) and did not respond to first treatment. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
Hear when a new Metastatic Colorectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.